Ultragenyx Pharmaceutical Inc. Files 8-K
Ticker: RARE · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $39.00, $38.999, $36.90375, $36.90275 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Ultragenyx just signed a big deal, filing an 8-K on June 13th.
AI Summary
On June 13, 2024, Ultragenyx Pharmaceutical Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Novato, California, filed this 8-K report with the SEC.
Why It Matters
This filing indicates a significant new agreement for Ultragenyx Pharmaceutical Inc., which could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Numbers
- 20240613 — Report Date (The filing reports on events occurring on or before this date.)
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Novato, California (location) — Address of principal executive offices
- 27-2546083 (identifier) — IRS Employer Identification No.
- 001-36276 (identifier) — Commission File Number
FAQ
What type of material definitive agreement did Ultragenyx Pharmaceutical Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on June 13, 2024.
What is Ultragenyx Pharmaceutical Inc.'s IRS Employer Identification Number?
Ultragenyx Pharmaceutical Inc.'s IRS Employer Identification Number is 27-2546083.
In which state was Ultragenyx Pharmaceutical Inc. incorporated?
Ultragenyx Pharmaceutical Inc. was incorporated in Delaware.
What is the address of Ultragenyx Pharmaceutical Inc.'s principal executive offices?
The principal executive offices of Ultragenyx Pharmaceutical Inc. are located at 60 Leveroni Court, Novato, California, 94949.
What is the Commission File Number for Ultragenyx Pharmaceutical Inc.?
The Commission File Number for Ultragenyx Pharmaceutical Inc. is 001-36276.
Filing Stats: 909 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2024-06-17 06:31:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select
- $39.00 — price to the public in the Offering is $39.00 per Share and $38.999 per Pre-Funded Wa
- $38.999 — in the Offering is $39.00 per Share and $38.999 per Pre-Funded Warrant, which is the pr
- $36.90375 — e Shares from the Company at a price of $36.90375 per Share and the Pre-Funded Warrants f
- $36.90275 — Warrants from the Company at a price of $36.90275 per Pre-Funded Warrant. In addition, pu
- $330.7 m — fering are expected to be approximately $330.7 million, after deducting the Underwriters
Filing Documents
- d785247d8k.htm (8-K) — 30KB
- d785247dex11.htm (EX-1.1) — 293KB
- d785247dex41.htm (EX-4.1) — 67KB
- d785247dex51.htm (EX-5.1) — 9KB
- g785247g0615112718150.jpg (GRAPHIC) — 2KB
- 0001193125-24-162003.txt ( ) — 624KB
- rare-20240613.xsd (EX-101.SCH) — 3KB
- rare-20240613_lab.xml (EX-101.LAB) — 17KB
- rare-20240613_pre.xml (EX-101.PRE) — 11KB
- d785247d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated as of June 13, 2024, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and TD Securities (USA) LLC 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Gibson, Dunn & Crutcher LLP 23.1 Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1) 104 The cover page from the Company's Current Report on Form 8-K dated June 13, 2024 formatted in Inline XBRL. * * *
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 17, 2024 Ultragenyx Pharmaceutical Inc. By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy